Skip to main content

Lichter Jay's Form 4 filing

Janux Therapeutics, Inc.JANX · filed Sep 10, 2024

Accession no.
0001415889-24-023153
Filed
Sep 10, 2024, 5:02 PM ET
Trade date
Sep 6-9, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $10.2M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lichter JayCIK 000137635510% Owner
Avalon Ventures XI, L.P.CIK 000165290110% Owner
Avalon BioVentures SPV I, L.P.CIK 000184455010% Owner
Avalon BioVentures I, LPCIK 000187393510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 6, 2024Common StockSSaleDisposed−108,365$42.00−$4,551,3303,162,851Direct
Sep 6, 2024Common StockSSaleDisposed−20,991$42.00−$881,622612,682Indirect
Sep 6, 2024Common StockSSaleDisposed−110,644$42.00−$4,647,0483,229,374Indirect
Sep 9, 2024Common StockMOption exerciseAcquired+994$17.00+$16,8988,077Direct
Sep 9, 2024Common StockMOption exerciseAcquired+414$10.73+$4,442.228,491Direct
Sep 9, 2024Common StockMOption exerciseAcquired+414$13.22+$5,473.088,905Direct
Sep 9, 2024Common StockMOption exerciseAcquired+277$39.80+$11,024.69,182Direct
Sep 9, 2024Common StockSSaleDisposed−2,182$42.33F5−$92,364.067,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 9, 2024Common StockMOption exerciseDisposed−994$0.00$029,006Direct
Sep 9, 2024Common StockMOption exerciseDisposed−414$0.00$012,086Direct
Sep 9, 2024Common StockMOption exerciseDisposed−414$0.00$012,086Direct
Sep 9, 2024Common StockMOption exerciseDisposed−277$0.00$08,073Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)